| COVID-19 |
1 |
1 |
| Immunization |
0 |
0.99 |
| Severe Acute Respiratory Syndrome |
0 |
0.98 |
| Acute Respiratory Distress Syndrome |
0 |
0.43 |
| Vaccines |
0 |
0.97 |
| Biologic Therapy |
0 |
0.15 |
| Glucocorticoid |
0 |
0.12 |
| Immunosuppressive Therapy |
0 |
0.12 |
| Connective Tissue Disease |
0 |
0.09 |
| Systemic Lupus Erythematosus |
0 |
0.96 |
| Antineoplastic Drug |
0 |
0.06 |
| Fellowship |
0 |
0.06 |
| Health Care Quality, Access, and Evaluation |
0 |
0.06 |
| Immunoglobulin A (IgA) |
0 |
0.06 |
| Lupus |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| Myositis |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Tissue |
0 |
0.06 |
| Scleroderma |
0 |
0.05 |
| Social Determinants of Health |
0 |
0.05 |